The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Mechanisms Controlling PD-L1 Expression in Cancer
Open accessAbstract
The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene) receptor expressed on activated T cells and its ligand programmed death-ligand 1 (PD-L1; encoded by the CD274 gene) is a major co-inhibitory checkpoint signaling that controls T-cell activities. Various types of cancers express high levels of PD-L1 and exploit the PD-L1/PD-1 signaling to evade T-cell immunity. Blocking the PD-L1/PD-1 pathway has consistently shown remarkable anti-tumor effects in patients with advanced cancers and is recognized as the gold standard for developing new immune checkpoint blockade (ICB) and combination therapies. However, the response rates of anti-PD-L1 have been limited in several solid tumors. Therefore, furthering our understanding of the regulatory mechanisms of PD-L1 can bring substantial benefits to patients with cancers by improving the efficacy of current PD-L1/PD-1 blockade or other ICBs. In this review article, we provide current knowledge of PD-L1 regulatory mechanisms at the transcriptional, posttranscriptional, post-translational, and extracellular level, and discuss the implications of these findings in cancer diagnosis and immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Self-citationCD8+ T Cells: Foot Soldiers of the Immune System
Zhang, N., & Bevan, M. J. (2011) · Immunity · doi:10.1016/j.immuni.2011.07.010 · Cited by 1,088
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Self-citationChen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
Self-citationPD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Cha, J.-H., Yang, W.-H., Xia, W., Wei, Y., Chan, L.-C., Lim, S.-O., Li, C.-W., Kim, T., Chang, S.-S., Lee, H.-H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.030 · Cited by 773
Self-citationA mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs
Chang, C.-J., Chao, C.-H., Xia, W., Yang, J.-Y., Xiong, Y., Li, C.-W., Yu, W.-H., Rehman, S. K., Hsu, J. L., Lee, H.-H., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2173 · Cited by 745
Self-citationMarzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M., Nuryadi, E., Sekine, R., Oike, T., Kakoti, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01883-9 · Cited by 702
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697
Mechanisms and principles of N-linked protein glycosylation
Schwarz, F., & Aebi, M. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.08.005 · Cited by 695
PDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 651
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Theodoraki, M.-N., Yerneni, S. S., Hoffmann, T. K., Gooding, W. E., & Whiteside, T. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2664 · Cited by 624
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 602
Self-citationHost expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96113 · Cited by 584
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Yao, H., Lan, J., Li, C., Shi, H., Brosseau, J.-P., Wang, H., Lu, H., Fang, C., Zhang, Y., Liang, L., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0375-6 · Cited by 568
Self-citationCoinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
Tang, H., Liang, Y., Anders, R. A., Taube, J. M., Qiu, X., Mulgaonkar, A., Liu, X., Harrington, S. M., Guo, J., Xin, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96061 · Cited by 524
Yang, Y., Li, C.-W., Chan, L.-C., Wei, Y., Hsu, J.-M., Xia, W., Cha, J.-H., Hou, J., Hsu, J. L., Sun, L., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0060-4 · Cited by 512
Self-citationJiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2731 · Cited by 485
The tumour glyco-code as a novel immune checkpoint for immunotherapy
RodrÍguez, E., Schetters, S. T. T., & van Kooyk, Y. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.3 · Cited by 473
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Hsu, J.-M., Xia, W., Hsu, Y.-H., Chan, L.-C., Yu, W.-H., Cha, J.-H., Chen, C.-T., Liao, H.-W., Kuo, C.-W., Khoo, K.-H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04313-6 · Cited by 434
Self-citationBET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J., Yokoyama, Y., Kossenkov, A. V., Bradner, J. E., Conejo-Garcia, J. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.032 · Cited by 432
Glycosylation-directed quality control of protein folding
Xu, C., & Ng, D. T. W. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4073 · Cited by 414
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Xu, C., Fillmore, C. M., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 391
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Chan, L.-C., Li, C.-W., Xia, W., Hsu, J.-M., Lee, H.-H., Cha, J.-H., Wang, H.-L., Yang, W.-H., Yen, E.-Y., Chang, W.-C., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126022 · Cited by 382
Self-citationZhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Zhou, J., Mahoney, K. M., Giobbie-Hurder, A., Zhao, F., Lee, S., Liao, X., Rodig, S., Li, J., Wu, X., Butterfield, L. H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0329 · Cited by 352
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M., Avramis, E., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 334
N-Linked Protein Glycosylation in the Endoplasmic Reticulum
Breitling, J., & Aebi, M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a013359 · Cited by 332 · cited 1×
“N-linked glycosylation of PD-L1 Glycosylation is the most abundant PTM found in one-third of all proteins in mammals (Breitling and Aebi, 2013).”
BackgroundWang, X., Yang, L., Huang, F., Zhang, Q., Liu, S., Ma, L., & You, Z. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.006 · Cited by 324
Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308
Twa, D. D. W., Chan, F. C., Ben-Neriah, S., Woolcock, B. W., Mottok, A., Tan, K. L., Slack, G. W., Gunawardana, J., Lim, R. S., McPherson, A. W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535443 · Cited by 302
Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y., Wang, T., Song, W., Chen, Y., OuYang, J., Chen, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11406 · Cited by 287
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Yang, Y., Hsu, J.-M., Sun, L., Chan, L.-C., Li, C.-W., Hsu, J. L., Wei, Y., Xia, W., Hou, J., Qiu, Y., et al. (2019) · Cell Research · doi:10.1038/s41422-018-0124-5 · Cited by 278
Self-citationThe MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
Lu, C., Paschall, A. V., Shi, H., Savage, N., Waller, J. L., Sabbatini, M. E., Oberlies, N. H., Pearce, C., & Liu, K. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw283 · Cited by 266
Tu, X., Qin, B., Zhang, Y., Zhang, C., Kahila, M., Nowsheen, S., Yin, P., Yuan, J., Pei, H., Li, H., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.04.005 · Cited by 263
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180870 · Cited by 242
Prestipino, A., Emhardt, A. J., Aumann, K., O’Sullivan, D., Gorantla, S. P., Duquesne, S., Melchinger, W., Braun, L., Vuckovic, S., Boerries, M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7729 · Cited by 229
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Zhang, J., Dang, F., Ren, J., & Wei, W. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.004 · Cited by 229
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Li, H., Li, C.-W., Li, X., Ding, Q., Guo, L., Liu, S., Liu, C., Lai, C.-C., Hsu, J.-M., Dong, Q., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.252 · Cited by 182
Self-citationIkeda, S., Okamoto, T., Okano, S., Umemoto, Y., Tagawa, T., Morodomi, Y., Kohno, M., Shimamatsu, S., Kitahara, H., Suzuki, Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.010 · Cited by 178
Okuma, Y., Hosomi, Y., Nakahara, Y., Watanabe, K., Sagawa, Y., & Homma, S. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.023 · Cited by 176
Essential role of HDAC6 in the regulation of PD‐L1 in melanoma
Lienlaf, M., Perez-Villarroel, P., Knox, T., Pabon, M., Sahakian, E., Powers, J., Woan, K. V., Lee, C., Cheng, F., Deng, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.012 · Cited by 170
Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1
Maher, C. M., Thomas, J. D., Haas, D. A., Longen, C. G., Oyer, H. M., Tong, J. Y., & Kim, F. J. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0166 · Cited by 164
Okuma, Y., Wakui, H., Utsumi, H., Sagawa, Y., Hosomi, Y., Kuwano, K., & Homma, S. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.014 · Cited by 151
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Carbotti, G., Barisione, G., Airoldi, I., Mezzanzanica, D., Bagnoli, M., Ferrero, S., Petretto, A., Fabbi, M., & Ferrini, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6530 · Cited by 149
The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
Wang, Q., Lin, W., Tang, X., Li, S., Guo, L., Lin, Y., & Kwok, H. F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122540 · Cited by 142
Microenvironmental regulation of cancer metastasis by miRNAs
Zhang, Y., Yang, P., & Wang, X. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.09.007 · Cited by 139
Pulko, V., Liu, X., Krco, C. J., Harris, K. J., Frigola, X., Kwon, E. D., & Dong, H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900974 · Cited by 122
YAMAGUCHI, H., Du, Y., Nakai, K., Ding, M., Chang, S. H., Hsu, J. L., Yao, J., Wei, Y., Nie, L., Jiao, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.311 · Cited by 121
Self-citationInhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing.
Sun, L., Yang, R., Li, C.-W., Chen, M., Shao, B., Hsu, J.-M., Chan, L.-C., Yang, Y., Hsu, J. L., Lai, Y., et al. (2018) · Europe PMC (PubMed Central) · Cited by 118
Self-citationDeng, S., Hu, Q., Zhang, H., Yang, F., Peng, C., & Huang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1068 · Cited by 116
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
D’Arrigo, P., Russo, M., Rea, A., Tufano, M., Guadagno, E., De, M. D. B., Pacelli, R., Hausch, F., Staibano, S., Ilardi, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19309 · Cited by 101
Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton
Horita, H. N., Law, A., Hong, S., & Middleton, K. M. (2017) · Neoplasia · doi:10.1016/j.neo.2017.02.006 · Cited by 91
NI, X. Y., Sui, H. X., Liu, Y., Ke, S. Z., Wang, Y. N., & GAO, F. G. (2012) · Oncology Reports · doi:10.3892/or.2012.1822 · Cited by 81
Quandt, D., Jasinski‐Bergner, S., Müller, U., Schulze, B., & Seliger, B. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-151 · Cited by 69
Xie, G., Li, W., Li, R., Wu, K., Zhao, E., Zhang, Y., Zhang, P., Shi, L., Wang, D., Yin, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168822 · Cited by 69
Shao, B., Li, C.-W., Lim, S., Sun, L., Lai, Y., Hou, J., Liu, C., Chang, C.-W. M., Qiu, Y., Hsu, J.-M., et al. (2018) · Europe PMC (PubMed Central) · Cited by 66
Self-citationSide-effects of checkpoint inhibitor-based combination therapy
Kourié, H. R., & Klastersky, J. A. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000295 · Cited by 50
A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas
Toyokawa, G., Takada, K., Tagawa, T., Hamamoto, R., Yamada, Y., Shimokawa, M., Oda, Y., & Maehara, Y. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.08.056 · Cited by 35
Cited by
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
Voli, F., Valli, E., Lerra, L., Kimpton, K., Saletta, F., Giorgi, F. M., Mercatelli, D., Rouaen, J. R. C., Shen, S., Murray, J. E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0471 · Cited by 411
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 328
Metadata
- Authors
- Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 76
- Issue
- 3
- Pages
- 359-370
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2982130750
- Cited by
- 1,045
- References
- 92
- FWCI
- 29.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.